Physician profile
Hamza Khan
NPI 1598323495
$1,662.99
in general payments reported to CMS, 2019-2025
28 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.06 · 2022: $107 · 2023: $388 · 2024: $99.99 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.87 |
| Education | $269.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $169.98 | 2023-2024 | |
| Lilly USA, LLC | $158.95 | 2022-2025 | Jaypirca, Verzenio |
| Astellas Pharma Global Development | $125.01 | 2023 | Padcev |
| Abbvie INC. | $125.00 | 2025 | |
| Incyte Corporation | $118.08 | 2025 | Jakafi, Niktimvo |
| Genzyme Corporation | $103.23 | 2023 | |
| Merck Sharp & Dohme LLC | $102.50 | 2025 | Keytruda Qlex, Keytruda, Welireg |
| E.R. Squibb & Sons, L.L.C. | $89.63 | 2023 | |
| Genentech, INC. | $82.87 | 2025 | |
| Tersera Therapeutics LLC | $56.39 | 2025 | Quzyttir, Xermelo |
| Janssen Biotech, INC. | $55.69 | 2025 | |
| Novartis Pharmaceuticals Corporation | $53.79 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $43.76 | 2025 | Calquence, Tagrisso |
| Glaxosmithkline, LLC. | $39.74 | 2025 | Ojjaara, Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $34.85 | 2025 | Ninlaro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $31.51 | 2025 | Onivyde |
| Coherus Oncology, INC. | $28.42 | 2025 | Loqtorzi |
| Rigel Pharmaceuticals, INC. | $28.15 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| Beone Medicines USA, INC. | $26.42 | 2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.02 | 2025 | |
| Daiichi Sankyo INC. | $25.08 | 2025 | Datroway |
| Genentech USA, INC. | $24.51 | 2025 | Venclexta |
| Puma Biotechnology, INC. | $22.34 | 2025 | |
| Shield Therapeutics INC | $20.79 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.06 | 2019 | |
| Caris Mpi, INC. | $19.74 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $16.41 | 2025 | |
| Adaptive Biotechnologies Corporation | $14.07 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.